Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
MWN-AI** Summary
Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology firm based in Huntsville, Alabama, has unveiled a new corporate communications platform aimed at enhancing engagement with patients, clinicians, investors, and the scientific community. This initiative aligns with the company’s commitment to transparency as it advances its proprietary POZ Platform ™ drug optimization technology.
CEO Steve Ledger emphasized the importance of clear communication in biotechnology, particularly as Serina prepares to launch its trial for SER-252, an investigational drug for Parkinson’s disease. The platform will offer a variety of resources, including regular updates on clinical programs, regulatory advancements, and educational opportunities aimed at improving the understanding of POZ-enabled therapeutics.
Key features of the communications platform include program updates available through the company’s website and newsletters, educational resources for medical professionals and patients, multimedia content such as a new podcast series, and interactive webinars to foster dialogue with stakeholders. These efforts are designed to enhance real-time access to information as Serina progresses with its clinical and regulatory activities.
The SER-252-1b study will be a randomized, double-blind, placebo-controlled Phase 1b trial assessing the safety and efficacy of SER-252, which utilizes Serina’s POZ platform to deliver continuous dopaminergic stimulation via a subcutaneous injection. This innovative delivery method, developed in collaboration with Enable Injections, aims to improve comfort and convenience for patients managing Parkinson’s disease.
As a clinical-stage company focused on neurology and beyond, Serina Therapeutics is dedicated to harnessing its technologies to create effective treatment solutions while keeping stakeholders informed of its journey. For more details, visit their website at [serinatx.com](https://serinatx.com).
MWN-AI** Analysis
Serina Therapeutics (NYSE American: SER) has made a significant move by launching an enhanced corporate communications platform aimed at fostering deeper engagement with its key stakeholders—patients, clinicians, and investors. This initiative coincides with the impending trial initiation for SER-252, its investigational therapy for Parkinson’s disease, underscoring the company's commitment to transparency and innovation.
From an investment perspective, the launch of this communications platform could serve as a positive signal for existing and potential investors. It indicates Serina's proactive approach towards maintaining open lines of communication—which is crucial in the biotechnology sector where timely information can notably affect stock performance. Investors should take note of Serina's dedication to delivering transparent updates regarding its clinical programs and regulatory advances, as these are key indicators of the company's trajectory.
Furthermore, the incorporation of diverse content, including educational resources and podcasts, suggests that Serina is not only focused on its clinical outcomes but also on building a more informed community around its products. Enhanced stakeholder engagement often correlates with increased investor confidence, particularly in clinical-stage companies where developments can be unpredictable.
As the SER-252 Phase 1b trial ramps up, stakeholders will be closely watching safety and efficacy data flow, especially given the competitive and transformative nature of Parkinson’s disease therapeutics. The trial's design and its focus on reducing motor fluctuations in advanced Parkinson’s patients position SER-252 uniquely in a space that is ripe for innovation.
In conclusion, investors should monitor updates from Serina’s newly launched platform for insights on clinical trial progress and broader market reception. Engaging with the content provided could enhance understanding of Serina’s strategic direction and inform investment decisions during this pivotal period in its developmental road map.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community.
The new initiative expands Serina’s direct channels of communication to provide stakeholders with clear, accessible information on the Company’s programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia content, and expert commentary from company leadership and scientific advisors.
“At Serina, we believe leadership in biotechnology requires not only advancing innovative science but also communicating that progress with clarity and transparency,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we prepare to initiate the planned trial of SER-252 in Parkinson’s disease, this new communications platform will serve as a vital resource for patients, clinicians, investors, and the broader scientific community. By providing timely updates and expert perspectives, we are ensuring that all stakeholders can follow our journey as we work to bring meaningful new treatment options to people living with Parkinson’s disease and other serious conditions.”
As part of the initiative, Serina plans to provide:
- Program and clinical updates delivered through the Company’s website and newsletters.
- Educational resources for physicians, patients, and scientists to better understand the potential of POZ-enabled therapeutics in improving therapeutic performance across multiple modalities.
- Multimedia content, including a new podcast series, to highlight perspectives from company leaders, investigators, and thought leaders in neuroscience and other therapeutic areas.
- Opportunities for engagement, including webinars and online forums to support dialogue with patient and professional communities.
This platform is designed to complement Serina’s ongoing clinical and regulatory activities, providing stakeholders with real-time access to relevant information as the Company advances its pipeline.
SER-252 Registrational Study Design Overview
The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by a Safety Review Committee and the study will be conducted across sites in the U.S. and Australia.
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS) via a single or twice-weekly subcutaneous injection. CDS has been shown to reduce the severity of motor fluctuations (which includes levodopa-induced dyskinesia) and enable greater daily on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse ™ wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform ™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com .
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ**
How does Serina Therapeutics Inc. SER plan to utilize its new corporate communications platform to enhance transparency regarding clinical trial updates for SER-252 in Parkinson’s disease?
In what ways does Serina Therapeutics Inc. SER intend to engage with stakeholders through its communications platform to ensure they stay informed about the safety and efficacy of SER-252?
What are the key safety and pharmacokinetics outcomes that Serina Therapeutics Inc. SER aims to assess in the Phase 1b trial of SER-252, and how will this impact its future development?
Can you elaborate on how the POZ Platform™ enhances the drug performance and delivery of SER-252 in Parkinson's disease treatment, according to Serina Therapeutics Inc. SER?
**MWN-AI FAQ is based on asking OpenAI questions about Serina Therapeutics Inc. (NYSE: SER).
NASDAQ: SER
SER Trading
95.7% G/L:
$2.505 Last:
117,994,996 Volume:
$2.10 Open:
